Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity: 2010-2021

Historic Liabilities and Shareholders Equity for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $2.0 billion.

  • Neurocrine Biosciences' Liabilities and Shareholders Equity rose 34.25% to $2.0 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $7.6 billion, marking a year-over-year increase of 32.86%. This contributed to the annual value of $1.7 billion for FY2020, which is 32.83% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Liabilities and Shareholders Equity of $2.0 billion as of Q3 2021, which was up 3.11% from $2.0 billion recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Liabilities and Shareholders Equity high stood at $2.0 billion for Q3 2021, and its period low was $289.4 million during Q1 2017.
  • Over the past 3 years, Neurocrine Biosciences' median Liabilities and Shareholders Equity value was $1.5 billion (recorded in 2020), while the average stood at $1.5 billion.
  • In the last 5 years, Neurocrine Biosciences' Liabilities and Shareholders Equity plummeted by 37.00% in 2017 and then skyrocketed by 178.67% in 2018.
  • Neurocrine Biosciences' Liabilities and Shareholders Equity (Quarterly) stood at $817.6 million in 2017, then climbed by 21.47% to $993.2 million in 2018, then soared by 31.50% to $1.3 billion in 2019, then soared by 32.83% to $1.7 billion in 2020, then skyrocketed by 34.25% to $2.0 billion in 2021.
  • Its Liabilities and Shareholders Equity stands at $2.0 billion for Q3 2021, versus $2.0 billion for Q2 2021 and $1.8 billion for Q1 2021.